Tech NewsNovo Nordisk’s semaglutide cuts BMI in children aged 6–11 in trialNovo Nordisk's phase 3 STEP Young trial found that weekly semaglutide, alongside diet and exercise, cut BMI in children aged 6 to under 12 with obesity over 68 weeks. The results were presented at ObesityWeek 2026 and published in the NEJM. Read More